A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

  • STATUS
    Recruiting
  • End date
    Dec 1, 2024
  • participants needed
    75
  • sponsor
    National Cancer Institute (NCI)
Updated on 12 September 2021
heparin
renal function
hearing loss
antiretroviral
measurable disease
carcinoma
lamivudine
entecavir
gilbert's disease
antivirals
progressive disease
neutrophil count
carboplatin
gemcitabine
pd-l1
aptt
neuropathy
urine test
cytotoxic agents
metastatic cancer
transitional cell carcinoma
m7824
metastatic urothelial carcinoma

Summary

Background

Metastatic urothelial carcinoma is lethal and has no cure. Response rates to current treatments are modest. Researchers want to find new strategies to treat the disease. In this study, they will test a drug called M7824. The drug is a new immunotherapy that blocks the pathways that cancer cells use to stop the immune system from fighting cancer.

Objective

To learn if M7824 can help the immune system s ability to fight urothelial cancer.

Eligibility

People age 18 and older who have urothelial cancer that has spread to other parts of their body and they have been previously treated with chemotherapy or immunotherapy

Design

Participants will be screened with a medical history and physical exam. They will have blood and urine tests. They will have imaging scans. They will have an electrocardiogram to measure heart function. Their ability to perform their normal activities will be evaluated. They may have a tumor biopsy. They will take a pregnancy test if needed.

Participants will repeat some of the screening tests during the study.

Treatment will be given in a series of 28-day cycles. Participants will get M7824 once every 2 weeks. It is given through an intravenous infusion. For this, a small plastic tube is put into an arm vein. They will get M7824 until their disease gets worse, they have unacceptable side effects, or they decide to stop treatment.

Participants will have a follow-up visit 30 days after treatment ends. Then they will be followed every 12 weeks in the clinic or by telephone/email. Follow-up will last indefinitely.

Description

Background
  • Metastatic urothelial carcinoma is lethal and incurable with a median overall survival of 14 months from diagnosis.
  • Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have greatly changed clinical management of metastatic urothelial carcinoma (mUC) improving survival by 3 months in the second-line setting.
  • Five PD-1/PD-L1 inhibitors are FDA-approved for for second-line mUC, two agents for first-line cisplatin-ineligible mUC. However, response rates are modest, ranging from15-20% in the second-line and 24% in the first-line cisplatin-ineligible.
  • Therefore, novel strategies are needed to extend benefit of immunotherapy to the remaining approximately 75% of non-responders.
  • Higher levels of transforming growth factor-beta (TGF-beta) are associated with immune escape, therapy resistance and poor outcomes in advanced malignancies. Non-responders to anti-PD-1/PD-L1 antibodies have also been found to have increased TGF-beta in the tumor microenvironment.
  • Bintrafusp alfa (M7824) is a novel first-in-class bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused to the extracellular domain of human TGF-beta receptor II (TGFbetaRII), which effectively functions to sequester or "trap" all three TGF-beta isoforms. A phase I study of M7824 (NCT02517398) demonstrated a manageable safety profile and clinical efficacy among patients with heavily pre-treated advanced solid tumors.
  • We hypothesize that M7824 is safe and improves outcomes in patients with checkpoint naive or refractory urothelial carcinoma.
    Objectives

-To evaluate the activity of M7824 as determined by objective response rate (ORR) in two metastatic urothelial carcinoma cohorts:

  • Cohort 1: Checkpoint inhibitor naive
  • Cohort 1A: cisplatin ineligible
  • Cohort 1B: refractory post-platinum therapy
  • Cohort 2: Checkpoint inhibitor previously treated patients
  • Cohort 2A: previously achieved a CR/PR
  • Cohort 2B: previously had SD/PD
    Eligibility
  • Patients must have a histologically confirmed diagnosis of metastatic urothelial cancer.
  • Patients may have been previously treated with prior cytotoxic chemotherapy regimen or targeted agent. Patients may have received any number of prior cytotoxic agents.
  • 18 years of age or older
    Design
  • This is an open label, non-randomized, single arm phase II trial of M7824 in checkpoint inhibitor naive and previously treated patients with urothelial carcinoma of the bladder.
  • M7824 (intravenous 1200 mg fixed dose) will be delivered every 2 weeks
  • Patients will receive treatment in cycles consisting of 4 weeks.
  • A maximum of 75 subjects will be enrolled in this trial.

Details
Condition Urothelial Cancer
Treatment Bintrafusp alfa (M7824)
Clinical Study IdentifierNCT04501094
SponsorNational Cancer Institute (NCI)
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Ability to understand the purpose of the study, provide signed and dated informed consent, and able to comply with all procedures
Male or female patients aged greater than or equal to 18 years of age at time of consent
Patients with histologically confirmed diagnosis of urothelial carcinoma of the urinary tract, including the renal pelvis, ureter, bladder, or urethra. Differentiation with variant histologies (e.g. squamous cell differentiated) will be permitted. Mixed histologies are required to have a dominant urothelial/transitional cell pattern
Patients must have metastatic disease defined as new or progressive lesions on crosssectional imaging. Radiological evaluation should occur within 21 days prior to enrollment
Patient must have evaluable and measurable disease, per RECIST 1.1
Patients may have been previously treated with prior cytotoxic chemotherapy regimen or targeted agent. Patients may have received any number of prior cytotoxic agents
Patients may have had prior immunomodulating therapy including therapy targeting the PD-1/PDL-1 axis (cohort 2A and B) but excluding prior treatment with M7824
Pre-treatment tissue biopsy and/or archival tissue availability for PD-L1 expression testing is mandatory for enrollment
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Required laboratory values reflective of organ function are listed below
Absolute neutrophil count greater than or equal to 1000/microliter
Platelets greater than or equal to 75,000 microliter
Hemoglobin greater than or equal to 9 g/dL (erythrocyte tranfusions are allowed to achieve acceptable Hgb)
AST(SGOT)/ALT(SGPT) less than or equal to 1.5 (SqrRoot) institutional upper limit of normal (ULN) with the following exception
\---Patients with liver involvement who have AST and ALT less than or equal to
(SqrRoot) ULN may be enrolled
Total bilirubin within normal limits with the following exceptions
Patients with known Gilbert disease who have serum bilirubin level less than or equal to 3 ULN may be enrolled
Patients with tumor liver involvement bilirubin with less than or equal to 3.0 (SqrRoot) ULN
INR and aPTT less than or equal to 1.5 (SqrRoot) ULN
\---This applies only to patients who are not receiving therapeutic
anticoagulation; patients receiving therapeutic anticoagulation (such as low-
molecular-weight heparin or warfarin) should be on a stable dose
Creatinine clearance (CrCl) greater than or equal to 30 mL/min/1.73 m^2 (GFR may be used in place of CrCl. Creatinine clearance or eGFR should be calculated per institutional standard)
The effects of M7824 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use strict and effective contraception (hormonal or barrier method of birth control; abstinence) during treatment and for at least 65 days for women and 125 days for men, after the last dose of M7824 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Human immunodeficiency virus (HIV) positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), CD4 counts are greater than 350 cells/mm3 and viral load is undetectable
Patients with previously treated brain or central nervous system (CNS) metastases are eligible provided that the subjects have recovered from any acute effects of radiotherapy and is not requiring steroids, and any whole brain radiation therapy or any stereotactic radiosurgery was completed at least 2 weeks prior to M7824 administration
Hepatitis B virus (HBV) positive patients are eligible-they must have been treated and on a stable dose of antivirals (eg, entecavir, tenofovir, or lamivudine; adefovir or interferon are not allowed) at study entry and with planned monitoring and management according to appropriate labeling guidance
Hepatitis C virus (HCV) positive patients are eligible if participants are on active HCV therapy at study entry and on a stable dose without documented clinically significant impaired liver function test or hematologic abnormalities and with planned monitoring and management according to appropriate labeling guidance
Cohort 1A Cisplatin Ineligible Specific Inclusion Criteria (first-line for metastatic cisplatin-ineligible)
No prior chemotherapy for inoperable locally advanced or metastatic or recurrent UC
\---For patients who received prior adjuvant/neoadjuvant chemotherapy or
chemoradiation for UC, a treatment-free interval > 12 months between the last
treatment administration and the date of recurrence is required in order to be
considered treatment naive in the metastatic setting. Prior local intravesical
chemotherapy or immunotherapy is allowed if completed at least 4 weeks prior
to the initiation of study treatment
Ineligible ("unfit") for chemotherapy or cisplatin-based chemotherapy as defined by any one of the following criteria
Impaired renal function (CrCl > 30 but < 60 mL/min); GFR should be calculated per institutional standard
A hearing loss (measured by audiometry) of 25 dB at two contiguous frequencies
Grade greater than or equal to 2 peripheral neuropathy (i.e., sensory alteration or paresthesias including tingling)
ECOG performance score of 2
Patient declines chemotherapy after informed discussion with the study doctor
Cohort 1B Refractory Post-platinum Therapy Specific Inclusion Criteria (second-line for metastatic disease)
\--Disease progression during or following treatment with a platinum-
containing regimen for inoperable locally advanced or metastatic urothelial
carcinoma or disease recurrence. Examples of regimens include cisplatin +
gemcitabine (GC), methotrexate + vinblastine sulfate + doxorubicin + cisplatin
(MVAC), and carboplatin + gemcitabine (CarboGem)
\---Patients who received prior adjuvant/neoadjuvant chemotherapy and
progressed within 12 months of treatment with a platinum-containing
adjuvant/neoadjuvant regimen will be considered as second-line patients
Cohort 2A Checkpoint Inhibitor Previously Treated Patients that Previously Achieved a Complete Response (CR) or Partial Respsonse (PR) Specific Inclusion Criteria
\--Patients must have been treated with at least one treatment of a PD-1/PD-L1
checkpoint inhibitor for advance or metastatic UC and achieved a complete
response or partial respsonse by RECIST 1.1 criteria
Cohort 2B Checkpoint inhibitor previously treated patients that previously had stable disease (SD) or progressive disease (PD)
Specific Inclusion Criteria
Patients must have been treated with at least one treatment of a PD-1/PD-L1 checkpoint inhibitor for advance or metastatic UC and had stable disease or a progressive disease by RECIST 1.1 criteria

Exclusion Criteria

History of allergic reactions attributed to compounds of similar chemical or biologic composition to M7824 investigational agents used in the study
Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Symptomatic central nervous system metastasis
Pregnant women are excluded from this study because M7824 is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M7824, breastfeeding should be discontinued if the mother is treated with these agents
Subjects unwilling to accept blood products as medically indicated
Patients with any active or recent history of a known or suspected autoimmune disease (with the exception of diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment) or recent history of a syndrome that required treatment with either systemic corticosteroids (>10 mg daily prednisone equivalent) or immunosuppressive medications. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients having tumor lesion(s) in the liver or chest which are 10 cm or larger
Patients with a currently active second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ or incidental organ-confined prostate cancer found on cystoprostatectomy (provided that the following criteria are met: Stage T2N0M0 or lower; Gleason score <= 3+4, PSA undetectable). Patients are not considered to have a currently active malignancy if they have completed therapy and are free of disease for >= 2 years and currently do not require systemic therapy
Patients previously treated with M7824
Patients who have received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus are permitted. Locally approved COVID vaccines are permitted
Patients previously treated with PD-1/PD-L1 checkpoint inhibitors (for Cohorts 1A and 1B only)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note